New-onset Fulminant Type 1 Diabetes Following COVID-19 Vaccination.

IF 1 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Internal Medicine Pub Date : 2025-03-22 DOI:10.2169/internalmedicine.5053-24

Takaaki Shigematsu, Yu Yamaguchi, Takeo Watanabe, Kazutaka Tsujimoto, Fuminori Sato, Tetsuya Yamada, Motoyoshi Tsujino

引用次数: 0

Abstract

A 31-year-old Japanese man was admitted with a slight fever and epigastric pain. He had received his third Moderna COVID-19 vaccine dose (Spikevax, mRNA-1273) 16 days before his visit. His serum amylase level was elevated, and computed tomography (CT) found pancreatic enlargement. Acute pancreatitis was diagnosed, and the patient was treated with fasting and intravenous fluids. However, on day 3 of hospitalization, his blood glucose level had increased to 320 mg/dL. His serum and urinary C-peptide were remarkably low (≤0.03 ng/mL and ≤0.6 μg/day, respectively) Finally, fulminant type 1 diabetes mellitus caused by the COVID-19 mRNA vaccine was diagnosed.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Internal Medicine 医学-医学：内科

CiteScore

1.90

自引率

8.30%

发文量

审稿时长

2.2 months

期刊介绍： Internal Medicine is an open-access online only journal published monthly by the Japanese Society of Internal Medicine. Articles must be prepared in accordance with "The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see Annals of Internal Medicine 108: 258-265, 1988), must be contributed solely to the Internal Medicine, and become the property of the Japanese Society of Internal Medicine. Statements contained therein are the responsibility of the author(s). The Society reserves copyright and renewal on all published material and such material may not be reproduced in any form without the written permission of the Society.